Event Details
Not specified
Description
ODYSSEY Phase 3 program: A comprehensive clinical trial program for PRALUENT, including 14 global trials with over 23,500 patients.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| patients | person | 2 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026366.jpg
This document is a corporate communication and product information sheet for the prescription drug Praluent (alirocumab), manufactured by Sanofi. It details the ODYSSEY clinical trial program, provides important safety information for patients, and includes a legal disclaimer. The document is marked with the identifier 'HOUSE_OVERSIGHT_026366' but contains no information whatsoever related to Jeffrey Epstein, his associates, finances, or travel.
Related Events
Events with shared participants
ODYSSEY Phase 3 program: A comprehensive clinical trial program for an investigational LDL cholesterol lowering therapy (Praluent), involving 14 global trials and over 23,500 patients.
Date unknown • Global
ODYSSEY Phase 3 program: A large-scale clinical trial program for the investigational LDL cholesterol-lowering therapy, Praluent (alirocumab), involving over 23,500 patients in 14 global trials.
Date unknown • Global
The ODYSSEY clinical trial program was conducted for the drug Praluent.
Date unknown • worldwide
Projected clinical trials for Parkinson's patients.
2016-01-01 • California (implied)
ODYSSEY clinical trial program.
2025-12-01
ODYSSEY Phase 3 program
Date unknown • Global
Stroke rehabilitation treatment program using imitation-based therapies.
Date unknown • Unspecified medical/research setting
Visit to Norman Geschwind's epilepsy clinic where he demonstrated symptoms of temporal lobe epilepsy (hypergraphia, religious conversion, hyposexuality) in patients to the narrator.
Date unknown • Epilepsy Clinic
Outbreak of food poisoning involving more than 100 patients.
2012-05-01 • Upstate New York
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event